What’s Trending?

Treatment involves adult patients with severe alopecia areata [...]
Tue, Oct 04, 2022
Source PharmaTimes
University of Lincoln and the University of Sheffield are researching how DNA could be repaired [...]
Tue, Oct 04, 2022
Source PharmaTimes
An obscure family of viruses, already endemic in wild African primates and known to cause fatal Ebola-like symptoms in some monkeys, is “poised for spillover” to humans, according to new University of Colorado Boulder research published online Sept. 30 in the journal Cell. [...]
Tue, Oct 04, 2022
Source WorldPharmaNews
The anti-inflammatory treatment is for Duchenne muscular dystrophy [...]
Mon, Oct 03, 2022
Source PharmaTimes
Events will raise awareness around the impact of atopic dermatitis across cultures [...]
Mon, Oct 03, 2022
Source PharmaTimes
The Nobel Assembly at Karolinska Institutet has today decided to award the 2022 Nobel Prize in Physiology or Medicine to Svante Pääbo for his discoveries concerning the genomes of extinct hominins and human evolution. [...]
Mon, Oct 03, 2022
Source WorldPharmaNews
A newly identified set of molecules alleviated pain in mice while avoiding the sedating affect that limits the use of opiates, according to a new study led by researchers at UC San Francisco. The molecules act on the same receptor as clonidine and dexmedetomidine - drugs commonly used in hospitals [...]
Fri, Sep 30, 2022
Source WorldPharmaNews
AstraZeneca
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk [...]
Thu, Sep 29, 2022
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews